Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Merck HCV genotype 1 drug receives CHMP positive opinion
The CHMP’s opinion was for the combination of Victrelis with peginterferon alfa and ribavirin, in adult patients with compensated liver disease who are previously untreated or who have
The CHMP’s opinion was for the combination of Victrelis with peginterferon alfa and ribavirin, in adult patients with compensated liver disease who are previously untreated or who have
Xiapex is a new non-surgical injectable treatment option for Dupuytren’s contracture in adult patients with a palpable cord. So far, Pfizer has paid $52.5m of regulatory milestones to
According to the latest move, the maximum allowable dosage of the drug for CPP changes from 90µg/kg/4 weeks to 180µg/kg/4 weeks. The Committee on Drug I, Pharmaceutical Affairs
The Phase 2 trial will assess the anti-tumor activity, tolerability and safety of retaspimycin HCl in combination with docetaxel as compared to docetaxel alone in approximately 100 second-
UST claims its PBV process technology makes it possible to achieve higher yields after drying and better stability during storage at ambient or even higher temperatures (including 37°C
The main objective of the trial is to assess the safety and tolerability of VP 20621 dosed orally for up to 14 days in adults previously treated for
Veeva CRM allows to manage customer information and interactions and features quick deployment, ease of use, cost efficiency and scalability. Veeva said its CRM application requires no hardware
Ulipristal acetate is an orally active selective progesterone receptor modulator that reversibly blocks the progesterone receptors in targeted tissues. It is marketed as ellaOne in Europe as well
The company has developed the anti malarial drug by utilizing its Dose Optimization Technology under the Novel Drug Delivery System (NDDS). ARH 1 carries Arteether 150mg/ml and is
Under the agreement, Unigene is expected utilize its peptide manufacturing technology to offer clinical supply material for a Phase 3 study of experimental drug CR845, to be conducted